Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

719927

Sigma-Aldrich

Resomer® RG 756 S, Poly(D,L-lactide-co-glycolide)

ester terminated, lactide:glycolide 75:25, Mw 76,000-115,000

Synonym(s):

PLGA

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Linear Formula:
[C3H4O2]x[C2H2O2]y
CAS Number:
26780-50-7
MDL number:
MFCD00131930
UNSPSC Code:
12162002
NACRES:
NA.23

Quality Level

200

form

amorphous

feed ratio

lactide:glycolide 75:25

mol wt

Mw 76,000-115,000

degradation timeframe

<6 months

viscosity

0.71-1.0 dL/g, 0.1 % (w/v) in chloroform(25 °C, Ubbelohde) (size 0c glass capillary viscometer)

transition temp

Tg 49-55 °C

storage temp.

2-8°C

SMILES string

O2C(C(=O)OC(C2=O)C)C.O1CC(=O)OCC1=O

InChI

1S/C6H8O4.C4H4O4/c1-3-5(7)10-4(2)6(8)9-3;5-3-1-7-4(6)2-8-3/h3-4H,1-2H3;1-2H2

InChI key

LCSKNASZPVZHEG-UHFFFAOYSA-N

Application

Controlled release
Poly (lactic-co-glycolic acid) 75:25 copolymer may be used to design a controlled drug delivery implant.

Legal Information

Product of Evonik
RESOMER is a registered trademark of Evonik Rohm GmbH

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCW7828
MKCV6333
MKCV6334
BCCH5996
BCCG5549

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

An in-situ forming implant formulation of naltrexone with minimum initial burst release using mixture of PLGA copolymers and ethyl heptanoate as an additive: In-vitro, ex-vivo, and in-vivo release evaluation.
Kamali H, et al.
Journal of drug delivery science and technology, 47, 95-105 (2018)
Igor Jeroukhimov et al.
Journal of the American College of Surgeons, 218(1), 102-107 (2013-11-12)
Chronic pain after inguinal hernia repair occurs in 16% to 62% of patients. The underlying mechanism probably involves sensory nerve damage and abnormal healing that might be influenced by the materials chosen for the procedure. We hypothesize that nonabsorbable sutures
Teresa Musumeci et al.
International journal of pharmaceutics, 440(2), 135-140 (2012-10-20)
Melatonin, a neurohormone secreted by the pineal gland, is able to modulate intraocular pressure (IOP). The aim of this study was to generate nanoparticle (NPs) sustained release formulations that allow to extend the pre-corneal residence time of melatonin, thus prolonging
Hannu Paajanen et al.
International journal of surgery (London, England), 11(1), 81-84 (2012-12-19)
Chronic pain may be a major long-term problem related to mesh material and operative trauma in inguinal hernioplasty. Lichtenstein hernioplasty was performed under local anaesthesia in 312 patients by the same surgeon and technique between 2003 and 2005. The patients
Daniel R Getts et al.
Nature biotechnology, 30(12), 1217-1224 (2012-11-20)
Aberrant T-cell activation underlies many autoimmune disorders, yet most attempts to induce T-cell tolerance have failed. Building on previous strategies for tolerance induction that exploited natural mechanisms for clearing apoptotic debris, we show that antigen-decorated microparticles (500-nm diameter) induce long-term
View All Related Papers

Articles

RESOMER® - Biodegradable Polymers for Sutures, Medical Devices, Drug Delivery Systems and Tissue Engineering

Interest in utilizing biodegradable polymers for biomedical applications has grown since the 1960s.

Poly(Glycerol Sebacate) in Tissue Engineering

Synthetic aliphatic polyesters dominate resorbable biomaterials in clinical use.

Biodegradable Polyester Nanoparticle Formation

AliAliphatic polyesters, including polylactide and polyglycolide, are biodegradable polymers widely used in medical applications.

Therapeutic Nanoparticles Harness Myeloid Cells for Brain Tumor-Targeted Delivery and Immunomodulation

Immunosuppressive tumor-associated myeloid cells (TAMC) are responsible for glioblastoma (GBM) resistance to immunotherapies and existing standard of care treatments. This mini-review highlights recent progress in implementing nanotechnology in advancing TAMC-targeted therapies for GBM.

See All

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service